{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033652","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.016648+00:00","generated_at":"2026-06-13T05:33:03.290700+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcadia begins strategic review, reports $18.8M cash and Q2 revenue guidance of $1.3-1.5M","bullets":["Strategic review initiated; Lake Street Capital Markets as advisor; options include sale, merger, or other transactions.","Cash and cash equivalents of $18.8M as of June 30, 2023; Q2 revenue expected between $1.3M and $1.5M.","Exiting ProVault and SoulSpring body care brands, saving $3-4M annually starting August 2023.","Expanded GoodWheat portfolio with launch of pancake mixes; Q2 results to be announced August 10, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033652","json":"https://secwatch.observer/filing/0000950170-23-033652.json","markdown":"https://secwatch.observer/filing/0000950170-23-033652.md","text":"https://secwatch.observer/filing/0000950170-23-033652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/0000950170-23-033652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/rkda-20230720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:33:03.290700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89b0e192726a9640012ef81dad3f85093bd2a189","claim":"Arcadia Biosciences, Inc. reported the second quarter of 2023 results: revenue $1.3 million - $1.5 million.","evidence_excerpt":"As of June 30, 2023, Arcadia Biosciences had approximately $18.8 million in cash and cash equivalents. The company anticipates second-quarter revenue in the range of $1.3 million - $1.5 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/0000950170-23-033652-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$1.3 million - $1.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}